Chemical Structure : QTX3034
CAS No.: 2972625-49-1
Catalog No.: PC-28071Not For Human Use, Lab Use Only.
QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-KRAS inhibitor that is efficacious against a broad spectrum of the more common KRASG12D-and KRASG12V-mutated cancers in vitro and in vivo.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 1 mg | $248 | In stock | |
| 5 mg | $548 | In stock | |
| 10 mg | Get quote | ||
| 25 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-KRAS inhibitor that is efficacious against a broad spectrum of the more common KRASG12D-and KRASG12V-mutated cancers in vitro and in vivo.
QTX3034 synergized with three different EGFR inhibitors (afatinib, cetuximab, erlotinib) to profoundly inhibit proliferation across multiple KRASG12D, KRASG12V, and KRASWT Amp mutant cell lines with strong ZIP synergy scores (>10).
Combination of QTX3034 and afatinib exhibited a markedly greater inhibitory effect on KRAS-mutant colony formation compared to the respective single agents.
QTX3034 induced a dose-dependent increase in EGFR phosphorylation in the KRASG12D-mutated cell line GP2D, while co-administration with afatinib robustly inhibited this EGFR activation.
| M.Wt | 663.24 | |
| Formula | C35H44ClFN8O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
3-chloro-5-((S)-2'-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6'-methyl-3,4,5',8'-tetrahydro-2H,6'H-spiro[naphthalene-1,7'-pyrido[4,3-d]pyrimidin]-4'-yl)-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxamide |
|
1. Yang J. Zhang, et al. Mol Cancer Ther (2023) 22 (12_Supplement): LB_C09.
2. Patent WO2024187174 A2 2024-09-12.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright